Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Chinook Therapeutics Inc (KDNY)  
$40.39 0.00 (0.00%) as of 4:30 Thu 8/10


Download
   
Exchange: N/A
Security Type: Common
Shares Out: 63,940,000
Market Cap: 2.58(B)
Last Volume: 0 Avg Vol: 0
52 Week Range: $21.56 - $40.39
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Chinook Therapeutics is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing precision medicines for kidney diseases. Co.'s pipeline is focused on kidney diseases with clinical pathways. Co.'s lead clinical program is atrasentan, an endothelin A receptor antagonist. Co.'s second product candidate, BION-1301, is an anti-APRIL monoclonal antibody also in development for patients with IgA nephropathy. Co. developing CHK-336 for the treatment of primary hyperoxaluria as well as secondary hyperoxaluria and idiopathic kidney stone formation. Co. is also conducting research programs in several other rare, severe chronic kidney diseases.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 10,000
Total Buy Value $0 $0 $0 $212,194
Total People Bought 0 0 0 1
Total Buy Transactions 0 0 0 1
Total Shares Sold 0 0 2,323 873,253
Total Sell Value $0 $0 $72,498 $19,325,721
Total People Sold 0 0 2 6
Total Sell Transactions 0 0 2 25
End Date 2024-02-29 2023-11-28 2023-05-30 2022-05-30

   
Records found: 475
  Page 15 of 19  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Brockstedt Dirk G. EVP of Research and Dev.   •       –      –    2017-04-03 4 AS $10.71 $85,645 D/D (8,000) 49,300     -
   Brockstedt Dirk G. EVP of Research and Dev.   •       –      –    2017-04-03 4 OE $0.45 $3,600 D/D 8,000 57,300     -
   Isaacs Stephen T President and CEO   •       •      –    2017-04-03 4 AS $10.28 $280,429 D/D (27,273) 102,200     -
   Isaacs Stephen T President and CEO   •       •      –    2017-04-03 4 OE $0.52 $14,182 D/D 27,273 129,473     -
   Isaacs Stephen T President and CEO   •       •      –    2017-03-13 4 AS $11.35 $309,434 D/D (27,273) 102,200     -
   Isaacs Stephen T President and CEO   •       •      –    2017-03-13 4 OE $0.52 $14,182 D/D 27,273 129,473     -
   Brockstedt Dirk G. EVP of Research and Dev.   •       –      –    2017-03-09 4 AS $11.00 $88,001 D/D (8,000) 49,300     -
   Brockstedt Dirk G. EVP of Research and Dev.   •       –      –    2017-03-09 4 OE $0.45 $3,600 D/D 8,000 57,300     -
   Dubensky Thomas W. Chief Scientific Officer   •       –      –    2017-03-09 4 AS $10.96 $274,078 D/D (25,000) 39,900     -
   Dubensky Thomas W. Chief Scientific Officer   •       –      –    2017-03-09 4 OE $0.52 $19,446 D/D 25,000 64,900     -
   Brockstedt Dirk G. EVP of Research and Dev.   •       –      –    2017-01-17 4 AS $11.86 $94,858 D/D (8,000) 49,300     -
   Brockstedt Dirk G. EVP of Research and Dev.   •       –      –    2017-01-17 4 OE $0.45 $3,600 D/D 8,000 57,300     -
   Templeman Blaine Executive VP, General Counsel   •       –      –    2017-01-11 4 AS $11.95 $45,231 D/D (3,785) 37,300     -
   Dubensky Thomas W. Chief Scientific Officer   •       –      –    2017-01-03 4 AS $11.16 $278,990 D/D (25,000) 39,900     -
   Dubensky Thomas W. Chief Scientific Officer   •       –      –    2017-01-03 4 OE $0.52 $13,000 D/D 25,000 64,900     -
   Isaacs Stephen T President and CEO   •       •      –    2017-01-03 4 AS $11.12 $303,289 D/D (27,273) 102,200     -
   Isaacs Stephen T President and CEO   •       •      –    2017-01-03 4 OE $0.52 $14,182 D/D 27,273 129,473     -
   Schafer Gregory W Chief Operating Officer   •       –      –    2016-12-23 4 OE $0.82 $28,700 D/D 35,000 120,979     -
   Isaacs Stephen T President and CEO   •       •      –    2016-12-15 4 GD $0.00 $0 I/I 51,000 70,657     -
   Isaacs Stephen T President and CEO   •       •      –    2016-12-01 4 AS $10.82 $295,169 D/D (27,273) 102,200     -
   Isaacs Stephen T President and CEO   •       •      –    2016-12-01 4 OE $0.52 $14,182 D/D 27,273 129,473     -
   Dubensky Thomas W. Chief Scientific Officer   •       –      –    2016-12-01 4 AS $10.94 $273,500 D/D (25,000) 39,900     -
   Dubensky Thomas W. Chief Scientific Officer   •       –      –    2016-12-01 4 OE $0.52 $25,893 D/D 25,000 64,900     -
   Haghighat Ross Director   –       •      –    2016-11-14 4 AS $15.50 $109,864 D/D (7,088) 81,880     -
   Isaacs Stephen T President and CEO   •       •      –    2016-11-14 4 AS $15.26 $416,050 D/D (27,273) 102,200     -
  475 Records found
  Previous  10  11  12  13  14  15  16  17  18  19   
  Page 15 of 19
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us